Article Information
- Received August 3, 2009
- Revision received August 27, 2009
- Accepted September 3, 2009
- First published October 28, 2009.
- Version of record published October 28, 2009.
Author Information
- Shane T. Hentges1,
- Veronica Otero-Corchon2,
- Reagan L. Pennock1,
- Connie M. King1, and
- Malcolm J. Low2,3
- 1Department of Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, and
- 2Center for the Study of Weight Regulation and
- 3Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon 97239
- Correspondence should be addressed to Shane T. Hentges, Colorado State University, Department of Biomedical Science–Neuroscience, 1617 Campus Delivery, Fort Collins, CO 80523-1617. hentgess{at}colostate.edu
Author contributions
Disclosures
- Received August 3, 2009.
- Revision received August 27, 2009.
- Accepted September 3, 2009.
-
This work was funded by National Institutes of Health Grants DK078749 and DK062219 (S.T.H.) and DK066604 (M.J.L.). The GAD67–gfp transgenic mice and tdimer2(12) DsRed plasmid were generously provided by Drs. Yuchio Yanagawa and Roger Tsien, respectively. We thank the Oregon Health & Science University Transgenic Core Laboratory for pronuclear microinjection of the POMC–DsRed transgene and Dr. John T. Williams for providing helpful insight on the experiments and this manuscript.
-
Dr. Low is the inventor of technology licensed to Orexigen Therapeutics Inc., a company that may have a commercial interest in the results of this research and technology. This potential conflict of interest has been reviewed and managed by the Oregon Health & Science University Conflict of Interest in Research Committee.
- Correspondence should be addressed to Shane T. Hentges, Colorado State University, Department of Biomedical Science–Neuroscience, 1617 Campus Delivery, Fort Collins, CO 80523-1617. hentgess{at}colostate.edu
